Therapeutic assembly

US 20040254419A1
Filed: 06/14/2004
Published: 12/16/2004
Est. Priority Date: 04/08/2003
Status: Abandoned Application

First Claim

Patent Images

1-177. -177. (Canceled) .

View all claims

2 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

A therapeutic assembly that contains a therapeutic agent, a ctyotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagentic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter

356 Citations

351 Claims

1-177. -177. (Canceled) .

178. A therapeutic assembly comprised of a first therapeutic agent, a cytotoxic radioactive material, and a nanomagnetic material comprised of nanomagnetic particles, wherein:
- (a) said nanomagnetic particles have an average particle size of less than about as 100 nanometers;
  
  (b) the average coherence length between adjacent nanomagnetic particles is less than as 100 nanometers; and
  
  (c) said nanomagnetic material has a saturation magnetization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter.
- View Dependent Claims (179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351)
- - 179. The therapeutic assembly as recited in claim 178, wherein said first therapeutic agent is an anti-cancer drug.
  - 180. The therapeutic assembly as recited in claim 178, wherein said first therapeutic agent is an anti-mitotic agent.
  - 181. The therapeutic assembly as recited in claim 178, wherein said assembly is comprised of a container and a cytotoxic radioactive material;
    - and wherein said nanomagnetic material has an average particle size of less than about as 20 nanometers and a phase transition temperature of less than about 50 degrees Celsius.
  - 182. The therapeutic assembly as recited in claim 181, wherein said cytotoxic radioactive material is disposed within said container.
  - 183. The therapeutic assembly as recited in claim 181, wherein said container is made of a material that is permeable to rays emanating from said cytotoxic radioactive material.
  - 184. The therapeutic assembly as recited in claim 183, wherein granules of radium chloride are disposed within said container.
  - 185. The therapeutic assembly as recited in claim 183, wherein particles of cesium-147 are disposed within said container.
  - 186. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material has a characteristic radiation substantially all of which lies between about 20 kev and 100 kev.
  - 187. The therapeutic assembly as recited in claim 181, wherein said container is in the shape of a tube with an outside diameter less than about 2 millimeters.
  - 188. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is iodine-125.
  - 189. The therapeutic assembly as recited in claim 188, wherein an X-ray marker is disposed within said container.
  - 190. The therapeutic assembly as recited in claim 181, wherein said cytotoxic radioactive material is disposed on the surface of said container.
  - 191. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is americium.
  - 192. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is cesium-137.
  - 193. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is selected from the group consisting of Xenon-131, Xenon-133, and mixtures thereof.
  - 194. The therapeutic assembly as recited in claim 181, wherein said container is made from a material which is absorbable in living tissue.
  - 195. The therapeutic assembly as recited in claim 181, wherein said container is in the form of a needle.
  - 196. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is selected from the group consisting of palladium-102, palladium-103, and mixtures thereof.
  - 197. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is gold-198.
  - 198. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is radon-222.
  - 199. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material has a substantially isotropic radial distribution of its radiation from within said container.
  - 200. The therapeutic assembly as recited in claim 181, wherein said container is made from a biocompatible material.
  - 201. The therapeutic assembly as recited in claim 181, wherein said container is made of a material that is absorbable in living tissue.
  - 202. The therapeutic assembly as recited in claim 201, wherein said material that is absorbable in living tissue is selected from the group consisting of polyester amides from glycolic acids, polyester amides from lactic acids, polymers and copolymers of glycolate, polymers and copolymers of lactate, and polydioxanone.
  - 203. The therapeutic assembly as recited in claim 182, wherein said cytotoxic radioactive material is iridium 192.
  - 204. The therapeutic assembly as recited in claim 181, wherein said container is a plastic container.
  - 205. The therapeutic assembly as recited in claim 181, wherein said container is a palladium container.
  - 206. The therapeutic assembly as recited in claim 181, wherein said container is a stainless steel container.
  - 207. The therapeutic assembly as recited in claim 182, wherein a carrier substrate onto which a radioisotope has been adsorbed on and is disposed within said container.
  - 208. The therapeutic assembly as recited in claim 181, wherein said container is a hollow tube.
  - 209. The therapeutic assembly as recited in claim 208, wherein said container is a sealed, double-walled hollow tube.
  - 210. The therapeutic assembly as recited in claim 181, wherein said container is constructed of a ferrous metal.
  - 211. The therapeutic assembly as recited in claim 181, wherein said container is a hermetically sealed container.
  - 212. The therapeutic assembly as recited in claim 178, wherein said therapeutic assembly is comprised of a polymeric material selected from the group consisting of a silicon-containing polymeric material and a hydrocarbon-containing polymeric material.
  - 213. The therapeutic assembly as recited in claim 179, wherein said assembly is comprised of a container.
  - 214. The therapeutic assembly as recited in claim 212, further comprising a container wherein said polymeric material is disposed above said container.
  - 215. The therapeutic assembly as recited in claim 212, wherein said polymeric material is comprised of said first therapeutic agent.
  - 216. The therapeutic assembly as recited in claim 215, wherein said polymeric material is comprised of a second therapeutic agent.
  - 217. The polymoric material therapeutic assembly as recited in claim 216, wherein said polymeric material is comprised of a third therapeutic agent.
  - 218. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a drug-eluting polymer.
  - 219. The therapeutic assembly as recited in claim 215, wherein said polymeric material is silicone rubber.
  - 220. The therapeutic assembly as recited in claim 219, wherein said silicone rubber is dimethylpolysiloxane rubber.
  - 221. The therapeutic assembly as recited in claim 219, wherein said silicone rubber is a biocompatible silicone rubber.
  - 222. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a synthetic absorbable copolymer formed by copolymerzing glycolide with trimethylene carbonate.
  - 223. The therapeutic assembly as recited in claim 215, wherein said polymeric material is selected from the group consisting of silk, polyester, polytetrafluoroethylene, polyurethane silicone-based material, and polyamide.
  - 224. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a bioresorbable polyester.
  - 225. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a copolymer containing carbonate repeat units and ester repeat units.
  - 226. The therapeutic assembly as recited in claim 215, wherein said polymeric material is collagen.
  - 227. The therapeutic assembly as recited in claim 215, wherein said polymeric material selected from the group consisting of homopolymers and copolymers of glycolic acid and lactic acid.
  - 228. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a polycarbonate-containing polymer.
  - 229. The therapeutic assembly as recited in claim 215, wherein said polymeric material is selected from the group consisting of polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polyamides, and copolyesters of polyamides and polyesters.
  - 230. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is dispersed in said polymeric material.
  - 231. The therapeutic assembly as recited in claim 215, wherein said polymeric material is selected from the group consisting of polyesters, polyamides, polyurethanes, and polyanhydrides.
  - 232. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a poly(phosphoester).
  - 233. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is selected from the group consisting of proteinaceous drugs and non-proteinaceous drugs.
  - 234. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is a biological response modifier.
  - 235. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is an immune modifier.
  - 236. The therapeutic assembly as recited in claim 235, wherein said immune modifier as a lymphokine.
  - 237. The therapeutic assembly as recited in claim 236, wherein said lymphokine is selected from the group consisting of tumor necrosis factor, interleukin, lymphotoxin, macrophage activating factor, migration inhibition factor, colony stimulating factor, and interferon.
  - 238. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is a lectin.
  - 239. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is bound within said polymeric material.
  - 240. The therapeutic assembly as recited in claim 215, wherein a multiplicity of therapeutic agents is disposed within said polymeric material.
  - 241. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a polypeptide.
  - 242. The therapeutic assembly as recited in claim 215, wherein said polymeric material is comprised of a first drug-binding domain.
  - 243. The therapeutic assembly as recited in claim 242, wherein said polymeric material is comprised of a second drug-binding domain.
  - 244. The therapeutic assembly as recited in claim 179, wherein said assembly is comprised of a reservoir for said therapeutic agent.
  - 245. The therapeutic assembly as recited in claim 244, wherein said therapeutic agent is selected from the group consisting of antithrombogenic agents, antiplatelet agents, prostaglandins, thrombolytic drugs, antiproliferative drugs, antirejection drugs, antimicrobial drugs, growth factors, anticalcifying agents, and mixtures thereof.
  - 246. The therapeutic assembly as recited in claim 245, wherein said reservoir is formed by a polymer selected from the group consisting of polyurethanes and its copolymers, silicone and its copolymers, ethylene vinylacetate, thermoplastic elastomers, polyvinylchloride, polyolefins, cellulosics, polyamides, polytetrafluoroethylenes, polyesters, polycarbonates, polysulfones, acrylics, and acrylonitrile butadiene styrene copolymers.
  - 247. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a bioabsorbable polymer selected from the group consisting of poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acid), cyanoacruylate, poly(trimethylene carbonate), poly(iminocarbonate) copoly(ether-ester), polyalkylene oxalate, polyphosphazenes, and mixtures thereof.
  - 248. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a biomolecule.
  - 249. The therapeutic assembly as recited in claim 248, wherein said biomolecule is selected from the group consisting of fibrin, fibrogen, cellulose, starch, collagen, and hyaluronic acid.
  - 250. The therapeutic assembly as recited in claim 215, wherein said polymeric material is selected from the group consisting of polyolefin, acrylic polymer, acrylic copolymer, vinyl halide polymer, vinyl halide copolymer, polyvinyl ether, polyvinylidene halide, polyvinylketone, polyvinyl aromatic polymer, copolymers of vinyl monomer, acrylonitrile-styrene copolymer, ethylene-vinyl acetate copolymer, polyamide, alkyd resin, polyoxymethylene, polyimide, polyether, epoxy resin, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ether, and carboxymethyl cellulose.
  - 251. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is selected from the group consisting of glucocorticoids, heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents.
  - 252. The therapeutic assembly as recited in claim 215, wherein a heterobifunctional photolytic linker is bonded to said polymeric material.
  - 253. The therapeutic assembly as recited in claim 252, wherein said heterobifunctional photolytic linker is bonded to said first therapeutic agent.
  - 254. The therapeutic assembly as recited in claim 253, further comprising means for releasing said first therapeutic agent from said heterobifunctional photolytic linker.
  - 255. The therapeutic assembly as recited in claim 254, wherein said means for releasing said first therapeutic agent from said heterobifunctional photolytic linker comprises a first coherent laser light source.
  - 256. The therapeutic assembly as recited in claim 255, wherein said coherent laser light source provides coherent light with a wavelength of from about 280 to about as 400 nanometers.
  - 257. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is a vasoreactive agent.
  - 258. The therapeutic assembly as recited in claim 257, wherein said vasoreactive agent is a nitric oxide releasing agent.
  - 259. The therapeutic assembly as recited in claim 215, wherein said polymeric material is comprised of a multiplicity of microcapsules.
  - 260. The therapeutic assembly as recited in claim 259 wherein said first therapeutic agent is disposed within said multiplicity of microcapsules.
  - 261. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a mixture of fibrinogen and thrombin.
  - 262. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a multi-layered polymeric material.
  - 263. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a porous polymeric material.
  - 264. The therapeutic assembly as recited in claim 215, wherein said polymeric material has a thermal processing temperature of less than about 100 degrees Celsius.
  - 265. The therapeutic assembly as recited in claim 215, wherein said polymeric material is comprised of a porosigen.
  - 266. The therapeutic assembly as recited in claim 265, wherein said porosigen is selected from the group of microgranules of sodium chloride, lactose, sodium heparin, polyethylene glycol, polyethylene oxide/polypropylene oxide copolymer, and mixtures thereof.
  - 267. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a thermoplastic polymer.
  - 268. The therapeutic assembly as recited in claim 215, wherein said polymeric material is an elastomeric polymer.
  - 269. The therapeutic assembly as recited in claim 215, wherein said polymeric material is in the form of a layer of material with a thickness of from about 0.002 to about 0.02 inches.
  - 270. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a controlled release polymer.
  - 271. The therapeutic assembly as recited in claim 270 wherein said controlled release polymer is comprised of a congener of an endothelium-derived bioactive composition.
  - 272. The therapeutic assembly as recited in claim 271, wherein said congener of an endothelium-derived bioactive agent is selected from the group consisting of nitric oxide, nitric L-arginine, sodium nitroprusside, and nitroglycerine.
  - 273. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a transparent polymeric material.
  - 274. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a hydrophobic elastomeric material.
  - 275. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a hydrophilic polymer.
  - 276. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is a water-soluble therapeutic agent.
  - 277. The therapeutic assembly as recited in claim 215, wherein said first therapeutic agent is an anti-microtubule agent that impairs the functioning of microtubuies.
  - 278. The therapeutic assembly as recited in claim 277, wherein said anti-microtubule agent is paclitaxel.
  - 279. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a pH-sensitive polymer.
  - 280. The therapeutic assembly as recited in claim 279, wherein said pH-sensitive polymer is selected from the group consisting of poly(acrylic acid), poly(aminocarboxylic acid), poly(acrylic acid), poly(methyl acrylic acid), cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate trimellitate, and chitosan.
  - 281. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a temperature-sensitive polymer.
  - 282. The therapeutic assembly as recited in claim 215, wherein said polymeric material is a thermogelling polymer.
  - 283. The therapeutic assembly as recited in claim 282, wherein said thermogelling polymer is selected from the group consisting of poly(methyl-N-n-propylacrylamide), poly(N-n-propylacrylamide), poly(N-methyl-N-isopropylacrylamide), poly(N-n-propylmethacrylamide), poly(N-isopropylacrylamide), poly(N,n-diethylacrylamide), poly(N-isopropylmethacrylamide), poly(N-cyclopropylacrylamide), poly(N-ethylmethyacrylamide), poly(N-methyl-N-ethylacrylamide), poly(N-cyclopropylmethacrylamide), and poly(N-ethylacrylamide), hydroxypropyl cellulose, methyl cellulose, hydroxypropylmethyl cellulose, and ethylhydroxyethyl cellulose.
  - 284. The therapeutic assembly as recited in claim 178, wherein the average particle size of said nanomagnetic particles is less than about as 15 nanometers.
  - 285. The therapeutic assembly as recited in claim 178, wherein said nanomagentic material has a saturation magnetization of at least 2,000 electromagnetic units per cubic centimeter.
  - 286. The therapeutic assembly as recited in claim 178, wherein said nanomagnetic material has a saturation magnetization of at least 2,500 electromagnetic units per cubic centimeter.
  - 287. The therapeutic assembly as recited in claim 178, wherein said particles of said nanomagnetic material have a squareness of from about 0.05 to about 1.0.
  - 288. The therapeutic assembly as recited in claim 178, wherein said particles of said nanomagnetic material are at least triatomic, being comprised of a first distinct atom, a second distinct atom, and a third distinct atom.
  - 289. The therapeutic assembly as recited in claim 288, wherein said first distinct atom is an atom selected from the group consisting of atoms of actinium, americium, berkelium, californium, cerium, chromium, cobalt, curium, dysprosium, einsteinium, erbium, europium, fermium, gadolinium, holmium, iron, lanthanum, lawrencium, lutetium, manganese, mendelevium, nickel, neodymium, neptunium, nobelium, plutonium, praseodymium, promethium, protactinium, samarium, terbium, thorium, thulium, uranium, and ytterbium.
  - 290. The therapeutic assembly as recited in claim 289, wherein said first distinct atom is an atom selected from the group consisting of iron, nickel, and cobalt.
  - 291. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material are comprised of a first distinct atom, a second distinct atom, a third distinct atom, and a fourth distinct atom.
  - 292. The therapeutic assembly as recited in claim 291, wherein said particles of nanomagnetic material are comprised of a fifth distinct atom.
  - 293. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a squareness of from about 0.1 to about 0.9.
  - 294. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a squareness is from about 0.2 to about 0.8.
  - 295. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have an average size of less of less than about as 3 nanometers.
  - 296. The therapeutic assembly as recited in claim 181, wherein said particles of nanomagnetic material have an average size of less than about as 15 nanometers.
  - 297. The therapeutic assembly as recited in claim 181, wherein said particles of nanomagnetic material have an average size of less than about as 11 nanometers.
  - 298. The therapeutic assembly as recited in claim 181, wherein said particles of nanomagnetic material have an average size of less than about as 3 nanometers.
  - 299. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a phase transition temperature of less than 46 degrees Celsius.
  - 300. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a phase transition temperature of less than about 50 degrees Celsius.
  - 301. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a phase transition temperature of less than about 46 degrees Celsius.
  - 302. The therapeutic assembly as recited in claim 178, wherein said nanomagnetic material has a coercive force of from about 0.1 to about 10 Oersteds.
  - 303. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material has a relative magnetic permeability of from about 1.5 to about 2,000.
  - 304. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a saturation magnetization of at least 100 electromagnetic units (emu) per cubic centimeter.
  - 305. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a saturation magnetization of at least about 200 electromagnetic units (emu) per cubic centimeter.
  - 306. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a saturation magnetization of at least about 1,000 electromagnetic units per cubic centimeter.
  - 307. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a coercive force of from about 0.01 to about 5,000 Oersteds.
  - 308. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a coercive force of from about 0.01 to about 3,000 Oersteds.
  - 309. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material are disposed within a film that has a heat shielding factor of at least 0.2.
  - 310. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a relative magnetic permeability of from about 1 to about 500,000.
  - 311. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a relative magnetic permeability of from about 1.5 to about 260,000.
  - 312. The therapeutic assembly as recited in claim 178, wherein said assembly is comprised of antithrombogenic material.
  - 313. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a mass density of at least about 0.001 grams per cubic centimeter.
  - 314. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a mass density of at least about 1 gram per cubic centimeter.
  - 315. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a mass density of at least about 3 grams per cubic centimeter.
  - 316. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material have a mass density of at least about 4 grams per cubic centimeter.
  - 317. The therapeutic assembly as recited in claim 288, wherein said second distinct atom has a relative magnetic permeability of about 1.0.
  - 318. The therapeutic assembly as recited in claim 288, wherein said second distinct atom is an atom selected from the group consisting of aluminum, antimony, barium, beryllium, boron, bismuth, calcium, gallium, germanium, gold, indium, lead, magnesium, palladium, platinum, silicon, silver, strontium, tantalum, tin, titanium, tungsten, yttrium, zirconium, magnesium, and zinc.
  - 319. The therapeutic assembly as recited in claim 318, wherein said third distinct atom is an atom selected from the group consisting of argon, bromine, carbon, chlorine, fluorine, helium, hydrogen, iodine, krypton, oxygen, neon, nitrogen, phosphorus, sulfur, and xenon.
  - 320. The therapeutic assembly as recited in claim 319, wherein said third distinct atom is an atom selected from the group consisting of oxygen and nitrogen.
  - 321. The therapeutic assembly as recited in claim 190, wherein said third distinct atom is nitrogen.
  - 322. The therapeutic assembly as recited in claim 288, wherein said nanomagnetic particles are represented by the formula A_xB_yC_z, wherein A is said first distinct atom, B is said second distinct atom, C is said third distinct atom, and x+y+z is equal to 1.
  - 323. The therapeutic assembly as recited in claim 322, wherein said third distinct atom is an atom selected from the group consisting of oxygen and nitrogen.
  - 324. The therapeutic assembly as recited in claim 323, wherein said third distinct atom is nitrogen.
  - 325. The therapeutic assembly as recited in claim 324, wherein said first distinct atom is iron.
  - 326. The therapeutic assembly as recited in claim 325, wherein said second distinct atom is aluminum.
  - 327. The therapeutic assembly as recited in claim 178, wherein said nanomagnetic material is disposed within a ceramic binder.
  - 328. The therapeutic assembly as recited in claim 327, wherein said ceramic binder is selected from the group consisting of a clay binder, an organic colloidal particle binder, and a molecular organic binder.
  - 329. The therapeutic assembly as recited in claim 178, wherein said nanomagnetic material is disposed within a synthetic polymeric binder.
  - 330. The therapeutic assembly as recited in claim 178, wherein said nanomagnetic material is disposed within a fiber.
  - 331. The therapeutic assembly as recited in claim 178, wherein said nanomagnetic material is disposed within a fabric.
  - 332. The therapeutic assembly as recited in claim 322 wherein the ratio of x/y is at least 0.1.
  - 333. The therapeutic assembly as recited in claim 322, wherein the ratio of x/y is at least 0.2.
  - 334. The therapeutic assembly as recited in claim 322, wherein the ratio of z/x is from about 0.001 to about 0.5.
  - 335. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagentic material have a saturation magnetization of from about 1 to about 36,000 Gauss, a coercive force of from about 0.01 to about 5,000 Oersteds, and a relative magnetic permeability of from about 1 to about 500,000.
  - 336. The therapeutic assembly as recited in claim 335, wherein said particles of nanomagnetic material have a saturation magnetization of from about 200 to about 26,000 Gauss.
  - 337. The therapeutic assembly as recited in claim 336, wherein said particles of nanomagnetic material are disposed within an insulating matrix.
  - 338. The therapeutic assembly as recited in claim 178, wherein said particles of nanomagnetic material are present in the form of a coating with a thickness of from about 400 to about 2000 nanometers.
  - 339. The therapeutic assembly as recited in claim 338, wherein said coating has a thickness of from about 600 to about 1200 nanometers.
  - 340. The therapeutic assembly as recited in claim 339, wherein said coating has a morphological density of at least about 98 percent.
  - 341. The therapeutic assembly as recited in claim 339, wherein said coating has a morphological density of at least about 99 percent.
  - 342. The therapeutic assembly as recited in claim 339, wherein said coating has a morphological density of at least about 99.5 percent.
  - 343. The therapeutic assembly as recited in claim 338, wherein said coating has an average surface roughness of less than about as 100 nanometers.
  - 344. The therapeutic assembly as recited in claim 338, wherein said coating has an average surface roughness of less than about as 10 nanometers.
  - 345. The therapeutic assembly as recited in claim 338, wherein said coating is biocompatible.
  - 346. The therapeutic assembly as recited in claim 338, wherein said coating is hydrophobic.
  - 347. The therapeutic assembly as recited in claim 338, wherein said coating is hydrophilic.
  - 348. The therapeutic assembly as recited in claim 338, wherein said coating has an average surface roughness of less than about as 1 nanometers.
  - 349. The therapeutic assembly as recited in claim 338, wherein said coating is contiguous with an interfacial diffusion layer.
  - 350. The therapeutic assembly as recited in claim 349, wherein said coating has a thickness of at least 150 nanometers.
  - 351. The therapeutic assembly as recited in claim 350, wherein said interfacial diffusion layer has a thickness of less than about as 10 nanometers.

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Biophan Technologies Incorporated
Original Assignee
Biophan Technologies Incorporated
Inventors
Connelly, Patrick R., Weiner, Michael L., Wang, Xingwu, Greenwald, Howard J., Lanzafame, John

Application Number

US10/867,517
Publication Number

US 20040254419A1
Time in Patent Office

Days
Field of Search
US Class Current

600/8
CPC Class Codes

A61K 45/06   Mixtures of active ingredie...

A61K 51/1262   Capsules

A61K 51/1286   Ampoules, glass carriers ca...

A61L 2300/416   Anti-neoplastic or anti-pro...

A61L 2300/44   Radioisotopes, radionuclides

A61L 2300/45   Mixtures of two or more dru...

A61L 31/16   Biologically active materia...

A61L 31/18   Materials at least partiall...

B82Y 15/00   Nanotechnology for interact...

B82Y 20/00   Nanooptics, e.g. quantum op...

Therapeutic assembly

First Claim

2 Assignments

0 Petitions

Accused Products

Abstract

356 Citations

351 Claims

Specification

Solutions

Use Cases

Quick Links

Therapeutic assembly

First Claim

2 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

356 Citations

351 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links